Nitroxide radical-containing nanoparticles attenuate tumorigenic potential of triple negative breast cancer

被引:48
作者
Shashni, Babita [1 ]
Nagasaki, Yukio [1 ,2 ,3 ]
机构
[1] Univ Tsukuba, Grad Sch Pure & Appl Sci, Dept Mat Sci, Tennoudai 1-1-1, Tsukuba, Ibaraki 3058573, Japan
[2] Univ Tsukuba, Grad Sch Comprehens Human Sci, Masters Sch Med Sci, Tennoudai 1-1-1, Tsukuba, Ibaraki 3058573, Japan
[3] Univ Tsukuba, CRiED, Tennoudai 1-1-1, Tsukuba, Ibaraki 3058573, Japan
关键词
Nitroxide radical-containing nanoparticle; Reactive oxygen species; Tumorigenesis; Breast cancer; Redox cancer therapy; REDOX NANOPARTICLES; OXIDATIVE STRESS; PROSTATE-CANCER; BIODISTRIBUTION; METASTASIS; CAROTENE; TOXICITY; TRIAL; RISK;
D O I
10.1016/j.biomaterials.2018.05.042
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
The critical importance of reactive oxygen species (ROS) as oncogene activators and essential secondary messengers in cancer cell survival have been widely reported. Since oxidative stress has been implicated as being pivotal in various cancers, antioxidant therapy seems an apt strategy to abrogate ROS-mediated cellular processes to attenuate cancers. We therefore synthesized ROS scavenging nitroxide radical containing nanoparticles (RNPs); pH insensitive RNPO and pH sensitive RNPN, to impede the proliferative and metastatic characteristics of the triple negative breast cancer cell line, MDA-MB-231, both in vitro and in vivo. RNPs significantly curtailed the proliferative and clonogenic potential of MDA-MB231 and MCF-7 cell lines. Inhibition of ROS-mediated migratory and invasive characteristics of MDA-MB-231, via down regulation of NF-kappa B and MMP-2, was also confirmed. Furthermore, a significant anti-tumor and anti-metastatic potential of RNPs was observed in an MDA-MB-231 mouse xenograft model. Such tumoricidal effects of RNPs were attained with negligible adverse effects, compared to conventional low molecular weight antioxidants, TEMPOL. Thus, the tumoricidal effects of RNPs are suggestive of insights on precedence of nanoparticle-based therapeutics over current low molecular weight antioxidants to curtail ROS-induced tumorigenesis of various cancers. (C) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:48 / 62
页数:15
相关论文
共 50 条
  • [41] Triple-negative breast cancer
    Reinaldo D Chacón
    María V Costanzo
    Breast Cancer Research, 12
  • [42] Basal/Triple Negative Breast Cancer
    Liedtke, C.
    Kiesel, L.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2009, 69 (04) : 309 - 315
  • [43] The clinical significance and biological function of olfactomedin 4 in triple negative breast cancer
    Xiong, Bin
    Lei, Xuefeng
    Zhang, Lei
    Fu, Jia
    BIOMEDICINE & PHARMACOTHERAPY, 2017, 86 : 67 - 73
  • [44] Advancement in triple-negative breast cancer therapeutics: A comprehensive review on the potential of cell membrane-coated nanoparticles
    Rout, Biswajit
    Agnihotri, Tejas Girish
    Jain, Aakanchha
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2024, 98
  • [45] Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer
    Cicin, Irfan
    Karagol, Hakan
    Usta, Ufuk
    Sezer, Atakan
    Uzunoglu, Sernaz
    Alas-Cosar, Rusen
    Yetisyigit, Tarkan
    Uygun, Kazim
    MEDICAL ONCOLOGY, 2009, 26 (03) : 335 - 343
  • [46] Potential Role of miRNA in Metastatic Cascade of Triple-Negative Breast Cancer
    Balkrishna, Acharya
    Mittal, Rashmi
    Arya, Vedpriya
    CURRENT CANCER DRUG TARGETS, 2021, 21 (02) : 153 - 162
  • [47] CD109 is a potential target for triple-negative breast cancer
    Tao, Ji
    Li, Hongbin
    Li, Qingwei
    Yang, Yu
    TUMOR BIOLOGY, 2014, 35 (12) : 12083 - 12090
  • [48] Is immune checkpoint modulation a potential therapeutic option in triple negative breast cancer?
    Klinke, David J., II
    BREAST CANCER RESEARCH, 2014, 16 (06):
  • [49] On the Therapeutic Potential of ERK4 in Triple-Negative Breast Cancer
    Boudghene-Stambouli, Fadia
    Soulez, Mathilde
    Ronkina, Natalia
    Doerrie, Anneke
    Kotlyarov, Alexey
    Seternes, Ole-Morten
    Gaestel, Matthias
    Meloche, Sylvain
    CANCERS, 2023, 15 (01)
  • [50] Therapeutic potential of ERK5 targeting in triple negative breast cancer
    Jesus Ortiz-Ruiz, Maria
    Alvarez-Fernandez, Stela
    Parrott, Tracy
    Zaknoen, Sara
    Burrows, Francis J.
    Ocana, Alberto
    Pandiella, Atanasio
    Esparis-Ogando, Azucena
    ONCOTARGET, 2014, 5 (22) : 11308 - 11318